CanSino gets COVID-19 vaccine patent from China’s IP regulator

CanSino Biologics has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, reported state media, citing documents from the country’s intellectual property regulator.

It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People’s Daily reported.

The paper cited documents published by China’s National Intellectual Property Administration saying that the patent was issued on August 11.

Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.